A new multiparametric classification in lung cancer patients - S.M.I.G.
The classification of bronchogenic carcinoma as a function of the prognosis is still an open field. The evaluation of stage, by use of the TNM system, and histologic cell type is not sufficient to guarantee a correct prognosis. The growth rate of the neoplasm is another important parameter. We propose a classification that takes into account the stage (S), histologic cell type (M), immune status (I) and the growth rate of the primary tumor (G): S.M.I.G. We studied 90 lung cancer patients according to the S.M.I.G. classification and we observed that their prognoses were directly correlated with their S.M.I.G. scores (the higher the score, the higher the 10-month mortality rate). The mortality rates within the first 10 months of follow-up were respectively 0%, 0%, 36.36%, 68%, 90.9% for the 5 groups obtained by S.M.I.G. The difference is statistically significant (P less than 0.0075) and there is a linear correlation between the mortality rate and the score assigned to each group (R = 0.943; P less than 0.05). The S.M.I.G. classification can predict the prognosis more efficiently than the usual classification (TNM) and histological cell type.
D000230:Adenocarcinoma / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification* / Q000276:immunology / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012882:Skin Tests